Molecular diagnostics
StemAxon has developed a molecular diagnostic and target readout for Alzheimer’s disease.
Source: LinkedIn company description · Retrieved October 13, 2026
StemAxon provides a platform for pharmaceutical companies to test lead compounds against Alzheimer’s disease.
Founded in 2016, StemAxon focuses on research and development related to neurodegenerative diseases, particularly sporadic Alzheimer’s disease and macular degeneration.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
StemAxon has developed a molecular diagnostic and target readout for Alzheimer’s disease.
Source: LinkedIn company description · Retrieved October 13, 2026
StemAxon created a ready-to-use kit mix with a protocol for neuronal research, including neuron-silicon interface research.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 18, 2026 and September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.